HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cemaliye Boylu Akyerli Selected Research

N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamide

10/2019Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cemaliye Boylu Akyerli Research Topics

Disease

1Hypoxia (Hypoxemia)
10/2019
1Neoplasms (Cancer)
10/2019
1Thyroid Neoplasms (Thyroid Cancer)
10/2019
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2005

Drug/Important Bio-Agent (IBA)

1Aurora KinasesIBA
10/2019
1N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamideIBA
10/2019
1Histone MethyltransferasesIBA
10/2019
1DNA (Deoxyribonucleic Acid)IBA
10/2019
1Pharmaceutical PreparationsIBA
10/2019
1MethyltransferasesIBA
10/2019
1Histone DemethylasesIBA
10/2019
1Histone Deacetylase InhibitorsIBA
10/2019
1Telomerase (Telomerase Reverse Transcriptase)IBA
10/2019
1SirtuinsIBA
10/2019
1leu-13 antigenIBA
03/2005